After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Nerve Renew is a dietary supplement designed to address neurological problems and restore healthy nerve function. The formula ...

The phase 2a trial showed rapid onset as well as long-lasting pain reduction with Algiax's allosteric GABAA-receptor modulator AP-325, setting up further trials of the drug. Neuropathic pain can ...

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company with a market capitalization of $35.05 million ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

"This medication — which is a drug that inhibits ... In addition to acute pain, suzetrigine may also be a solution for neuropathic (nerve) pain, depending on the results of further studies ...

The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.